SCHEMBL19902501

SCHEMBL19902501

Cn1ncc2cc(C(=O)N[C@H]3CC[C@H](c4n[nH]c(=O)c5ccccc54)CC3)ccc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER3 P43115 2/20 0.47
ROCK2 O75116 1/20 0.45
HPGD P15428 1/20 0.44
CCNC P24863 3/20 0.42
CDK8 P49336 3/20 0.42
HTR2A P28223 1/20 0.42
PASK Q96RG2 1/20 0.42
CDK19 Q9BWU1 1/20 0.42
HPGDS O60760 1/20 0.42
MAPK14 Q16539 4/20 0.42
KHK P50053 1/20 0.42
MAOB P27338 2/20 0.41
MAOA P21397 1/20 0.41
ACHE P22303 1/20 0.41
LCK P06239 1/20 0.40
KIT P10721 1/20 0.40
KDR P35968 1/20 0.40
LRRK2 Q5S007 1/20 0.40
MLLT1 Q03111 2/20 0.40
KDM4E B2RXH2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19902479 0.93 KHK (0.48) PTGER3ROCK2HPGDCCNCCDK8
SCHEMBL17452888 0.89 ROCK2 (0.59) PTGER3ROCK2CCNCCDK8HTR2A
SCHEMBL19902707 0.86 KDM5A (0.49) ROCK2HPGDHPGDSMAPK14KDM4E
SCHEMBL19902622 0.83 MAPK14 (0.54) ROCK2HPGDMAPK14KHKKDM4E
SCHEMBL19902708 0.82 HPGD (0.48) ROCK2HPGDKDM4EALDH1A1
SCHEMBL17452898 0.82 ROCK2 (0.59) PTGER3ROCK2CCNCCDK8HTR2A
SCHEMBL19902605 0.80 CCNC (0.55) ROCK2CCNCCDK8
SCHEMBL19902369 0.80 ROCK2 (0.46) ROCK2MAPK14MAOB
SCHEMBL19902620 0.80 ROCK2 (0.40) ROCK2CCNCCDK8MAPK14LCK
SCHEMBL19902593 0.79 USP30 (0.54) ROCK2CCNCCDK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180155296-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK BRISTOL MYERS SQUIBB CO (US) 2018-06-07 US disclosed
US-9902702-B2 Spirocycloheptanes as inhibitors of rock BRISTOL-MYERS SQUIBB COMPANY (US) 2018-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180155296-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK ROCK1, MYLK, ROCK2 PTGER3 105/4885ROCK2 3/4885HPGD 749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.